Avoro Capital Advisors LLC Cyma Bay Therapeutics, Inc. Transaction History

Avoro Capital Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $10.2 Million - $19.8 Million	811,111 Added 7.87%	11,111,111 $262 Million
Q3 2020 Nov 16, 2020	BUY	$3.32 - $7.24 $16.8 Million - $36.6 Million	5,050,000 Added 96.19%	10,300,000 $74.6 Million
Q2 2020 Aug 14, 2020	SELL	$1.41 - $4.25 $352,500 - $1.06 Million	-250,000 Reduced 4.55%	5,250,000 $18.3 Million
Q4 2019 Feb 14, 2020	BUY	$1.33 - $5.93 $3.72 Million - $16.6 Million	2,800,000 Added 103.7%	5,500,000 $10.8 Million
Q2 2019 Aug 14, 2019	BUY	$6.05 - $13.66 $11.9 Million - $27 Million	1,975,000 Added 272.41%	2,700,000 $19.3 Million
Q1 2019 May 15, 2019	BUY	$8.16 - $13.42 $5.92 Million - $9.73 Million	725,000 New	725,000 $9.63 Million
Q3 2018 Nov 14, 2018	SELL	$10.88 - $14.52 $14 Million - $18.6 Million	-1,282,374 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$10.66 - $14.38 $13.7 Million - $18.4 Million	1,282,374 New	1,282,374 $17.2 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Avoro Capital Advisors LLC with notifications on news.